Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy

Benjamin W. Teh; Constantine S. Tam

doi:10.1080/10428194.2021.1957879

Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Original language	English
Pages (from-to)	2820-2822
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	62
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2021.1957879
Publication status	Published - 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2021.1957879

Cite this

@article{bfdbb66062c14f52928a021bc99a8e61,

title = "Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy",

author = "Teh, {Benjamin W.} and Tam, {Constantine S.}",

note = "Funding Information: BWT is supported by Australian Government National Health and Medical Research Council early career fellowship and Medical Research Future Fund investigator fellowship. Funding Information: BWT is on the advisory board for CSL-Behring and has received research funding from Merck Sharp and Dohme, Gilead Sciences. CST has research funding and honorarium from Beigene, Janssen and AbbVie.",

year = "2021",

doi = "10.1080/10428194.2021.1957879",

language = "English",

volume = "62",

pages = "2820--2822",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "12",

}

TY - JOUR

T1 - Between a rock and a hard place

T2 - COVID-19 vaccination and patients on rituximab therapy

AU - Teh, Benjamin W.

AU - Tam, Constantine S.

N1 - Funding Information: BWT is supported by Australian Government National Health and Medical Research Council early career fellowship and Medical Research Future Fund investigator fellowship. Funding Information: BWT is on the advisory board for CSL-Behring and has received research funding from Merck Sharp and Dohme, Gilead Sciences. CST has research funding and honorarium from Beigene, Janssen and AbbVie.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85111700470&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1957879

DO - 10.1080/10428194.2021.1957879

M3 - Comment / Debate

C2 - 34313175

AN - SCOPUS:85111700470

SN - 1042-8194

VL - 62

SP - 2820

EP - 2822

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy

UN SDGs

Access to Document

Other files and links

Cite this